S&P 500
7,615.40
-0.09%
Dow Jones
51,321.50
-0.10%
Nasdaq 100
30,653.20
-0.20%
Russell 2000
2,931.58
-0.05%
FTSE 100
10,377.00
-0.11%
Nikkei 225
68,476.70
+1.44%

Investing

Pre-Market Stock News (Oct. 3, 2007)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published

(AAI) AirTran load factor rose 6.7% to 68.5%.
(BEAS) BEA Systems stake raised to 11% by Carl Icahn.
(BOBE) Bob Evans s-s-s rose 0.4%.
(CPST) Capstone Turbine received a microturbine order for for $3.8 million in Germany.
(CTCT) Constant Contact IPO priced at $16, above the $12 to $14 range.
(DB) Deutsche Bank disclosed it will take over $3 Billion in charges.
(DUSA) DUSA Pharma’s Levulan Kerastick received marketing approval in South Korea.
(MBRX) Metabasis rose over 10% on EU Orphan drug status for liver cancer drug study.
(MFA) MFA Mortgage priced a 7 million share secondary offering at $7.90 per share.
(MU) Micron traded down 2% after earnings on cautious commentary.
(OSIS) OSI Systems won a $30 million government contract for carge inspection.
(PFCB) P.F.Chang’s lowered guidance; stock down over 10%.
(PNRA) Panera s-s-s +1.5%; sees $0.35-0.37 EPS vs prior $0.32-0.38 range.
(RPM) RPM Corp. $0.53 EPS vs $0.55 est.
(SVR) Syniverse wins data clearing deal from VimpelCom in Russia.
(TASR) Taser received a follow-on order from U.S. Marshalls.
(VZ) Verizon launches iPhone answers for 2007 holiday season.

Jon C. Ogg
October 3, 2007

Follow 24/7 Wall St. on Google
Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

Pre-Market Stock News (June 14, 2007)

(APPAD) AP Pharmaceuticals announces the pricing of its underwritten public offering of 21.2 million shares of its common stock at…

Jon C. Ogg |

BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

There are more recognized stocks in today’s edition of the BioHealth Business Daily.  We are seeing significant and unusual moves,…

Douglas A. McIntyre |

Biotech Business Daily (AMLN, CERS, LLY, DNA, GTOP, IMCL)

Amylin Pharmaceuticals (NASDAQ: AMLN) reported first quarter losses of $68.8 million, or $0.51 EPS, wider than the $49.4 million in…

Douglas A. McIntyre |

Pre-Market Stock News (September 13, 2007)

(AINV) Apollo Investment priced a 13 million share secondary at $20.00.(ALU) Alcatel-Lucent lowered full year revenue guidance.(ANPI) Angiotech Pharma said…

Douglas A. McIntyre |

Does Dusa (DUSA) Run Too Hard?

Dusa Pharmaceuticals (DUSA) received "orphan drug status" for its for Levulan photodynamic therapy for the treatment of esophageal dysplasia, a…

Douglas A. McIntyre |

Biotech Business Daily (CHTP, CRXL, LLY, IOMI, MEDX, TRCA)

Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP) falling today after first quarter earnings showed wider losses than first quarter 2007. Net…

Douglas A. McIntyre |

Pre-Market Stock News (MAR 29, 2007)

(ALTR) Altera announced a $0.04 dividend a 50 million share buyback plan.(ALV) Autoliv names new President/CEO.(ANGO) Angiodynamics fell 20% after…

247sam |

Today’s Market Winners and Losers

The stock market is down Thursday, with the Dow Jones Industrial Average down 0.23%, the Nasdaq down 0.18% and the…

Top 6 Biopharma Movers of the Past Week
Chris Lange |

Top 6 Biopharma Movers of the Past Week

Over the past week, Opko Health, Acadia Pharmaceuticals and a few other biotech companies made impressive runs.

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 153,197,465
Enphase Energy
ENPH • Vol: 8,360,053
Corning
GLW • Vol: 18,152,646
Alexandria Real Estate Equities
ARE • Vol: 4,337,015
Aptiv
APTV • Vol: 6,761,325

Top Losing Stocks

Trade Desk
TTD • Vol: 21,905,513
Intuit
INTU • Vol: 7,383,018
Coterra Energy
CTRA • Vol: 73,319,495
Cboe Global Markets
CBOE • Vol: 5,000,011
HP
HPQ • Vol: 29,259,826